Cheng-Xue Dang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheng-Xue Dang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Hao Zhang
Xi’an Jiaotong University College of Medicine
4 shared publicationsYong-Chun Song
4 shared publicationsDongmei Diao
Oncology Department, the First Affiliated Hospital, Xi'an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsKun Zhu
Oncology Department, the First Affiliated Hospital, Xi'an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsYao Cheng
Oncology Department, the First Affiliated Hospital, Xi'an Jiaotong University, Xi’an, Shaanxi, China
2 shared publicationsYongchun Song
Xi’an Jiaotong University College of Medicine
2 shared publications
Latest Publications
- 21 August 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (4) , 695
Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients
Prior studies have demonstrated that analysis of gene promoter methylation in stool samples may be a potential biomarker for noninvasive colorectal cancer detection. Aberrant methylation in gene promoter is common in various cancers, and epigenetic alterations can result in down-regulation or silence of gene expression. Recently, hypermethylation of fibrillin-1 (FBN1) was reported to be associated with colorectal cancer (CRC). In this study, we examined the methylation status of FBN1 in stool samples to test CRC. For the purpose of colorectal cancer detection, we investigated FBN1 hypermethylation in the tissue and stool samples of colorectal cancer patients using methylation-specific polymerase chain reaction. The result is that out of 75 patients with colorectal cancer, 59 (78.7 %) exhibited hypermethylated FBN1 in their tumor tissue DNA. We next detected the methylation status of FBN1 in the stool DNA of these patients. The hypermethylated FBN1 occurred in 72 % (54/75) of these patients in their stool samples and occurred in 6.7 % (2/30) of healthy people (P < 0.001). The results indicated 72.0 % sensitivity and 93.3 % specificity of the test for detecting CRC by using stool samples. So, the study reveals that hypermethylation status in the promoter of FBN1 is a high specific and sensitive biomarker for colorectal cancer, and detecting hypermethylated FBNI in stool samples is a noninvasive and useful method for screening colorectal cancer.
- 21 August 2013
- Published by Springer Nature in Medical Oncology
- Vol. 30 (4) , 695
Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients
Prior studies have demonstrated that analysis of gene promoter methylation in stool samples may be a potential biomarker for noninvasive colorectal cancer detection. Aberrant methylation in gene promoter is common in various cancers, and epigenetic alterations can result in down-regulation or silence of gene expression. Recently, hypermethylation of fibrillin-1 (FBN1) was reported to be associated with colorectal cancer (CRC). In this study, we examined the methylation status of FBN1 in stool samples to test CRC. For the purpose of colorectal cancer detection, we investigated FBN1 hypermethylation in the tissue and stool samples of colorectal cancer patients using methylation-specific polymerase chain reaction. The result is that out of 75 patients with colorectal cancer, 59 (78.7 %) exhibited hypermethylated FBN1 in their tumor tissue DNA. We next detected the methylation status of FBN1 in the stool DNA of these patients. The hypermethylated FBN1 occurred in 72 % (54/75) of these patients in their stool samples and occurred in 6.7 % (2/30) of healthy people (P < 0.001). The results indicated 72.0 % sensitivity and 93.3 % specificity of the test for detecting CRC by using stool samples. So, the study reveals that hypermethylation status in the promoter of FBN1 is a high specific and sensitive biomarker for colorectal cancer, and detecting hypermethylated FBNI in stool samples is a noninvasive and useful method for screening colorectal cancer.
- Open Access
- 19 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e73238
Ratio of Metastatic to Examined Lymph Nodes, a Helpful Staging System and Independent Prognostic Factor of Esophagogastric Junction Cancer
The incidence of the esophagogastric junction cancer is growing rapidly. The purpose of this study is to clarify the outcome of the ratio between metastatic and examined lymph nodes in esophagogastric junction cancer patients with or without 7 examined lymph nodes. A total of 3,481 patients who underwent operation are identified from the Surveillance, Epidemiology, and End Results database. Different lymph nodes resected groups are analyzed to test the lymph nodes ratio factor. There are 2522 patients with 7 or more lymph nodes resected and 959 patients with less than 7 lymph nodes resected. Lymph nodes ratio and lymph node involvement are independent prognostic factors. But the lymph nodes ratio categories have a better prognostic value than the lymph node involvement categories. Compared with lymph node involvement categories, lymph nodes ratio categories represent patients with more homogeneous overall survival rate. This study defines that the lymph nodes ratio is an independent prognostic factor for esophagogastric junction cancer. The lymph nodes ratio can prevent stage migration and may be a helpful system to predict the prognosis of esophagogastric junction cancer patients.
- 19 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e73238
Open AccessRatio of Metastatic to Examined Lymph Nodes, a Helpful Staging System and Independent Prognostic Factor of Esophagogastric Junction Cancer
The incidence of the esophagogastric junction cancer is growing rapidly. The purpose of this study is to clarify the outcome of the ratio between metastatic and examined lymph nodes in esophagogastric junction cancer patients with or without 7 examined lymph nodes. A total of 3,481 patients who underwent operation are identified from the Surveillance, Epidemiology, and End Results database. Different lymph nodes resected groups are analyzed to test the lymph nodes ratio factor. There are 2522 patients with 7 or more lymph nodes resected and 959 patients with less than 7 lymph nodes resected. Lymph nodes ratio and lymph node involvement are independent prognostic factors. But the lymph nodes ratio categories have a better prognostic value than the lymph node involvement categories. Compared with lymph node involvement categories, lymph nodes ratio categories represent patients with more homogeneous overall survival rate. This study defines that the lymph nodes ratio is an independent prognostic factor for esophagogastric junction cancer. The lymph nodes ratio can prevent stage migration and may be a helpful system to predict the prognosis of esophagogastric junction cancer patients.
- Open Access
- 13 July 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 155
Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China
Background: The incidence of adenocarcinoma of the esophagogastric junction is increasing. This study aims to evaluate the clinicopathological features of Chinese patients with adenocarcinoma of the esophagogastric junction and to define prognostic factors. Methods: We retrospectively reviewed a database of 382 consecutive patients with adenocarcinoma of the esophagogastric junction at the First Affiliated Hospital of Xi’an Jiaotong University from January 2005 to March 2010. All patients were classified according to the Siewert’s classification and staged according to the latest edition of the American Joint Committee on Cancer categories. Results: Six of the 382 patients had type I adenocarcinoma, 220 had type II, and 156 had type III. There was no significant difference in the overall survival of different Siewert subtypes. According to the multivariate analysis, pathological lymph node stage, age, and the existence of lymphovascular invasion were the independent factors of prognosis of adenocarcinoma of the esophagogastric junction following surgery. Conclusions: On the data, the distribution of the three types of tumor was found to be different from that reported in Western countries. Lymph node metastasis, lymphovascular invasion, and age were significant and independent factors for poor prognosis after R0 resection for adenocarcinoma of the esophagogastric junction.
- 13 July 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 155
Open AccessAdenocarcinomas of the esophagogastric junction: experiences at a single institution in China
Background: The incidence of adenocarcinoma of the esophagogastric junction is increasing. This study aims to evaluate the clinicopathological features of Chinese patients with adenocarcinoma of the esophagogastric junction and to define prognostic factors. Methods: We retrospectively reviewed a database of 382 consecutive patients with adenocarcinoma of the esophagogastric junction at the First Affiliated Hospital of Xi’an Jiaotong University from January 2005 to March 2010. All patients were classified according to the Siewert’s classification and staged according to the latest edition of the American Joint Committee on Cancer categories. Results: Six of the 382 patients had type I adenocarcinoma, 220 had type II, and 156 had type III. There was no significant difference in the overall survival of different Siewert subtypes. According to the multivariate analysis, pathological lymph node stage, age, and the existence of lymphovascular invasion were the independent factors of prognosis of adenocarcinoma of the esophagogastric junction following surgery. Conclusions: On the data, the distribution of the three types of tumor was found to be different from that reported in Western countries. Lymph node metastasis, lymphovascular invasion, and age were significant and independent factors for poor prognosis after R0 resection for adenocarcinoma of the esophagogastric junction.
- 15 May 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 108 (1) , 34-41
Prognostic value of the D‐dimer test in oesophageal cancer during the perioperative period
Background: There has been little research on the perioperative D‐dimer levels in oesophageal cancer patients. Plasma D‐dimer levels can be used to predict the outcome in cancer patients.Methods: A cancer group of 66 oesophageal cancer patients and a control group of 12 patients with benign disease were enrolled in this cohort study. The plasma D‐dimer levels during the pre‐operation and 3rd and 9th day post‐operation periods were prospectively examined and analysed between the two groups. Plasma D‐dimer levels were also compared with the clinicopathological characteristics and 3‐year survival of the oesophageal cancer patients.Results: Plasma D‐dimer levels increased in both groups after surgery, but they were significantly higher in the cancer group. In oesophageal cancer patients, pre‐operation plasma D‐dimer levels were significantly higher in TNM stage IV patients. Perioperative plasma D‐dimer levels significantly increased after surgery, and the survival was shortened in those patients whose D‐dimer levels on the 3rd and 9th post‐operative day above the median. In addition, increased plasma D‐dimer levels at the 3rd and 9th days after surgery were influenced by the patient's age.Conclusion: In oesophageal cancer patients, D‐dimer levels increased after surgery, and the increases were associated with poor outcomes. J. Surg. Oncol. 2013 108:34–41.
- 15 May 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 108 (1) , 34-41
Prognostic value of the D‐dimer test in oesophageal cancer during the perioperative period
Background: There has been little research on the perioperative D‐dimer levels in oesophageal cancer patients. Plasma D‐dimer levels can be used to predict the outcome in cancer patients.Methods: A cancer group of 66 oesophageal cancer patients and a control group of 12 patients with benign disease were enrolled in this cohort study. The plasma D‐dimer levels during the pre‐operation and 3rd and 9th day post‐operation periods were prospectively examined and analysed between the two groups. Plasma D‐dimer levels were also compared with the clinicopathological characteristics and 3‐year survival of the oesophageal cancer patients.Results: Plasma D‐dimer levels increased in both groups after surgery, but they were significantly higher in the cancer group. In oesophageal cancer patients, pre‐operation plasma D‐dimer levels were significantly higher in TNM stage IV patients. Perioperative plasma D‐dimer levels significantly increased after surgery, and the survival was shortened in those patients whose D‐dimer levels on the 3rd and 9th post‐operative day above the median. In addition, increased plasma D‐dimer levels at the 3rd and 9th days after surgery were influenced by the patient's age.Conclusion: In oesophageal cancer patients, D‐dimer levels increased after surgery, and the increases were associated with poor outcomes. J. Surg. Oncol. 2013 108:34–41.
- Open Access
- 1 January 2013
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 10 (3) , 230-234
Detection of Hypermethylated Spastic Paraplegia-20 in Stool Samples of Patients with Colorectal Cancer
Analysis of aberrant hypermethylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer. To explore the feasibility of detecting hypermethylation in Spastic paraplegia-20 promoter as a stool-based DNA marker for detection of colorectal cancer. We collected 96 tissue and stool samples from patients with colorectal cancer and 30 stool samples healthy individuals. Hypermethylated Spastic paraplegia-20 occurs in 85.4% (82/96) of patients with colorectal cancer in the tissue samples. In the stool samples, the results indicate 80.2% (77/96) sensitivity and 100% (30/30) specificity of the test for detecting colorectal cancer by using the stool samples as a noninvasive method. The study reveals that hypermethylation in Spastic paraplegia-20 promoter is a highly specific and sensitive biomarker for screening colorectal cancer in stool samples as a noninvasive method.
- 1 January 2013
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 10 (3) , 230-234
Open AccessDetection of Hypermethylated Spastic Paraplegia-20 in Stool Samples of Patients with Colorectal Cancer
Analysis of aberrant hypermethylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer. To explore the feasibility of detecting hypermethylation in Spastic paraplegia-20 promoter as a stool-based DNA marker for detection of colorectal cancer. We collected 96 tissue and stool samples from patients with colorectal cancer and 30 stool samples healthy individuals. Hypermethylated Spastic paraplegia-20 occurs in 85.4% (82/96) of patients with colorectal cancer in the tissue samples. In the stool samples, the results indicate 80.2% (77/96) sensitivity and 100% (30/30) specificity of the test for detecting colorectal cancer by using the stool samples as a noninvasive method. The study reveals that hypermethylation in Spastic paraplegia-20 promoter is a highly specific and sensitive biomarker for screening colorectal cancer in stool samples as a noninvasive method.
- 1 March 2012
- Vol. 32 (3) , 296-300
[Responses of pancreatic cancer cells to stimulations by nerve growth factor and the role of Trk-A expression].
To study the responses of different pancreatic cancer cells to stimulations by nerve growth factor (NGF) and explore the role of Trk-A in such responses. Five pancreatic cancer cell lines (MIA-PaCa-2, PANC-1, SW-1990, AsPC-1, and BxPC-3) were exposed to different concentrations of NGF (0, 4, 20, 100, and 500 ng/ml). MTT and Matrigel invasion method were used to observe the changes in the cell proliferation and invasion ability. Trk-A expression in these cells was detected by PCR and Western blotting, and the relations of Trk-A expression to the cell proliferative and invasive abilities following NGF treatment were analyzed. NGF at 100 ng/ml most obviously stimulated the cell proliferation, and PANC-1 cells showed the highest while AsPC-1 cells showed the least sensitivity to 100 ng/ml NGF stimulation. Matrigel invasion test showed that NGF enhanced the invasiveness of PANC-1 and MIA-PaCa-2 cells but produced only limited effect on AsPC-1 cells; the effect of NGF was completely inhibited by the Trk-A inhibitor CEP701. The expression levels of Trk-A mRNA and protein were the highest in PANC-1 cells and the lowest in AsPC-1 cells. NGF can enhance the proliferation and invasiveness of pancreatic cancer cells, and this effect is possibly mediated by Trk-A protein.
- 1 March 2012
- Vol. 32 (3) , 296-300
[Responses of pancreatic cancer cells to stimulations by nerve growth factor and the role of Trk-A expression].
To study the responses of different pancreatic cancer cells to stimulations by nerve growth factor (NGF) and explore the role of Trk-A in such responses. Five pancreatic cancer cell lines (MIA-PaCa-2, PANC-1, SW-1990, AsPC-1, and BxPC-3) were exposed to different concentrations of NGF (0, 4, 20, 100, and 500 ng/ml). MTT and Matrigel invasion method were used to observe the changes in the cell proliferation and invasion ability. Trk-A expression in these cells was detected by PCR and Western blotting, and the relations of Trk-A expression to the cell proliferative and invasive abilities following NGF treatment were analyzed. NGF at 100 ng/ml most obviously stimulated the cell proliferation, and PANC-1 cells showed the highest while AsPC-1 cells showed the least sensitivity to 100 ng/ml NGF stimulation. Matrigel invasion test showed that NGF enhanced the invasiveness of PANC-1 and MIA-PaCa-2 cells but produced only limited effect on AsPC-1 cells; the effect of NGF was completely inhibited by the Trk-A inhibitor CEP701. The expression levels of Trk-A mRNA and protein were the highest in PANC-1 cells and the lowest in AsPC-1 cells. NGF can enhance the proliferation and invasiveness of pancreatic cancer cells, and this effect is possibly mediated by Trk-A protein.
- 1 February 2011
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 10 (2) , 92-95
ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy
- 1 February 2011
- Published by Springer Nature in The Chinese-German Journal of Clinical Oncology
- Vol. 10 (2) , 92-95
ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy
- 16 March 2010
- Vol. 90 (10) , 703-7
[Vitexicarpin affects proliferation and apoptosis in mutated p53 breast cancer cell].
To elucidate the effect of proliferation and apoptosis induced by vitexicarpin in mutated p53 Hs578T cell line and study the expression of c-Myc, p21 and Bcl-2 protein in Hs578T and wild p53 MCF-7 cell pre-treated with vitexicarpin. Cells were treated with various concentrations of vitexicarpin (0, 0.1, 0.2, 0.5, 1.0 micromol/L). MTT assays were used to detect cell proliferation at different time points with different doses of vitexicarpin. TUNEL assays were performed to examine apoptosis in cells pretreated with vitexicarpin. The authors detected three main proteins involved in apoptosis: c-Myc, bcl-2 and p21 protein in various concentrations of vitexicarpin-treated cells. To understand the function of c-Myc protein in the effect of vitexicarpin, the authors transiently transfected c-Myc protein in Hs578T cell and detected the cellular effect of vitexicarpin. Proliferation of Hs578T and MCF-7 cells were inhibited markedly by vitexicarpin at concentrations above 0.2 micromol/L (IC50 = 0.25 micromol/L and 0.53 micromol/L at 72 h respectively). TUNEL assays revealed that the rates of TUNEL positive cells were 10.15%, 27.33% and 35.34% when exposing Hs578T cells to 0.1, 0.2 and 0.5 micromol/L of vitexicarpin respectively. In control cells, the rates of TUNEL positive cells were 4.65%. Cells pretreated with higher concentrations of vitexicarpin expressed less c-Myc and Bcl-2 in Hs578T cells.In contrast, p21 decreased when cells were treated with the same conditions. When c-Myc transient transfection was performed in vitexicarpin-treated cells, the effect of p21 and Bcl-2 disappeared. The proliferative function of vitexicarpin declined in Hs578T/c-Myc cells. When treated with 0.5 micromol/L vitexicarpin, A value increased 1.53 times at 72 h. Conversely, A value decreased 48% at the same condition in MCF-7/c-Myc cells. The suppressing mechanism of vitexicarpin for malignant tumors is through c-Myc in p53 mutated Hs578T cells. And it is multi-directional and varies in different cells.
- 16 March 2010
- Vol. 90 (10) , 703-7
[Vitexicarpin affects proliferation and apoptosis in mutated p53 breast cancer cell].
To elucidate the effect of proliferation and apoptosis induced by vitexicarpin in mutated p53 Hs578T cell line and study the expression of c-Myc, p21 and Bcl-2 protein in Hs578T and wild p53 MCF-7 cell pre-treated with vitexicarpin. Cells were treated with various concentrations of vitexicarpin (0, 0.1, 0.2, 0.5, 1.0 micromol/L). MTT assays were used to detect cell proliferation at different time points with different doses of vitexicarpin. TUNEL assays were performed to examine apoptosis in cells pretreated with vitexicarpin. The authors detected three main proteins involved in apoptosis: c-Myc, bcl-2 and p21 protein in various concentrations of vitexicarpin-treated cells. To understand the function of c-Myc protein in the effect of vitexicarpin, the authors transiently transfected c-Myc protein in Hs578T cell and detected the cellular effect of vitexicarpin. Proliferation of Hs578T and MCF-7 cells were inhibited markedly by vitexicarpin at concentrations above 0.2 micromol/L (IC50 = 0.25 micromol/L and 0.53 micromol/L at 72 h respectively). TUNEL assays revealed that the rates of TUNEL positive cells were 10.15%, 27.33% and 35.34% when exposing Hs578T cells to 0.1, 0.2 and 0.5 micromol/L of vitexicarpin respectively. In control cells, the rates of TUNEL positive cells were 4.65%. Cells pretreated with higher concentrations of vitexicarpin expressed less c-Myc and Bcl-2 in Hs578T cells.In contrast, p21 decreased when cells were treated with the same conditions. When c-Myc transient transfection was performed in vitexicarpin-treated cells, the effect of p21 and Bcl-2 disappeared. The proliferative function of vitexicarpin declined in Hs578T/c-Myc cells. When treated with 0.5 micromol/L vitexicarpin, A value increased 1.53 times at 72 h. Conversely, A value decreased 48% at the same condition in MCF-7/c-Myc cells. The suppressing mechanism of vitexicarpin for malignant tumors is through c-Myc in p53 mutated Hs578T cells. And it is multi-directional and varies in different cells.
- Open Access
- 21 December 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 454
Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer
Background: Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis. We developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear DNA (nDNA). We sought to investigate whether mtDNA content in the peripheral blood of breast cancer patients is associated with clinical and pathological parameters. Methods: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-matched healthy individuals as control. DNA was extracted from peripheral blood for the quantification of mtDNA and nDNA, using a one-step multiplex real-time PCR. A FAM labeled MGB probe and primers were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein. Results: The content of mtDNA in stage I breast cancer patients was significantly lower than in other stages (overall P = 0.023). Reduced mtDNA was found often in post menopausal cancer group (P = 0.024). No difference in mtDNA content, in regards to age (p = 0.564), lymph node involvement (p = 0.673), ER (p = 0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed. Conclusion: Early detection of breast cancer has proved difficult and current detection methods are inadequate. In the present study, decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly associated with stage I. The use of mtDNA may have diagnostic value and further studies are required to validate it as a potential biomarker for early detection of breast cancer.
- 21 December 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 454
Open AccessDecreased mitochondrial DNA content in blood samples of patients with stage I breast cancer
Background: Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis. We developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear DNA (nDNA). We sought to investigate whether mtDNA content in the peripheral blood of breast cancer patients is associated with clinical and pathological parameters. Methods: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-matched healthy individuals as control. DNA was extracted from peripheral blood for the quantification of mtDNA and nDNA, using a one-step multiplex real-time PCR. A FAM labeled MGB probe and primers were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein. Results: The content of mtDNA in stage I breast cancer patients was significantly lower than in other stages (overall P = 0.023). Reduced mtDNA was found often in post menopausal cancer group (P = 0.024). No difference in mtDNA content, in regards to age (p = 0.564), lymph node involvement (p = 0.673), ER (p = 0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed. Conclusion: Early detection of breast cancer has proved difficult and current detection methods are inadequate. In the present study, decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly associated with stage I. The use of mtDNA may have diagnostic value and further studies are required to validate it as a potential biomarker for early detection of breast cancer.
- 1 July 2007
- Vol. 26 (7)
[Expression and Significance of BP1 Gene and Cyclin D1 Gene in Breast Cancer].
BP1, a novel transcriptional factor, belongs to DLX family of homeobox genes. Recent researches showed that BP1 gene is correlated to genesis of breast cancer, but its correlation to cell cycle control factor has not been reported yet. This study was to observe the expression of BP1 in breast cancer, and to make clear its correlation to Cyclin D1.
- 1 July 2007
- Vol. 26 (7)
[Expression and Significance of BP1 Gene and Cyclin D1 Gene in Breast Cancer].
BP1, a novel transcriptional factor, belongs to DLX family of homeobox genes. Recent researches showed that BP1 gene is correlated to genesis of breast cancer, but its correlation to cell cycle control factor has not been reported yet. This study was to observe the expression of BP1 in breast cancer, and to make clear its correlation to Cyclin D1.